# Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer

> **NCT03487939** · PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Neoplasms
- Drug Therapy

## Interventions

- **DRUG:** FOLFOXIRI

## Key facts

- **NCT ID:** NCT03487939
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2021-10-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03487939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03487939, "Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT03487939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*